My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 8 451 / DOI: 10.3332/ecancer.2014.451

Policy

NHS reforms in England: the implications for chemotherapy commissioning

For oncology, one of the biggest effects of the reforms to the National Health Service (NHS) in England has been the designation of systemic anticancer treatments (other than hormonal agents) as a specialised service. This means that all decisions regarding the commissioning of chemotherapy are made at the national level via NHS England (NHSE), under expert guidance from the Chemotherapy Clinical Reference Group (CRG). Commissioning decisions will be based on several factors, not only clinical efficacy and cost/affordability, but also the ‘added value’ that a new treatment may offer in terms of patient outcomes, resource utilisation, and/or wider benefits to society. Oncology health-care professionals (HCPs) are in a position to affect cancer commissioning decisions in the reformed NHS, not only the small number who are members of the Chemotherapy CRG, but also as advisors to the Chemotherapy CRG via disease-specific consensus work, and through participation in the collection and reporting of real-life data on patient outcomes. With the emerging emphasis on both consensus work and outcomes data, a step change can also be expected in the relationship between HCPs and the pharmaceutical industry, including a strengthened role for non-promotional education, support for forums and consensus groups, and facilitation of the development, collection, and dissemination of findings from real-life practice. In addition, there will be an onus on the pharmaceutical industry to provide information on the implications that new products may have for service delivery and capacity and for meeting patients’ and society’s expectations. This information will need to be developed and delivered in a timely way, well in advance of the launch of a new product.

Keywords: Cancer Drugs Fund, Clinical Commissioning Groups, Clinical Reference Groups, NHS England, systemic anticancer treatment, value-based assessment

Categories:

Economics Medicines

Loading Article Metrics ... Please wait

Related articles

Special Issue: The past and future of breast cancer treatment—from the papyrus to individualised treatment approaches

Abstract | Full Article | PDF Published: 08 Jun 2017 / DOI: 10.3332/ecancer.2017.746

Image Report: Brachytherapy and anterior segment imaging in iris melanoma

Abstract | Full Article | PDF Published: 18 Apr 2017 / DOI: 10.3332/ecancer.2017.734

Case Report: Unusual tumour ablations: report of difficult and interesting cases

Abstract | Full Article | PDF Published: 18 Apr 2017 / DOI: 10.3332/ecancer.2017.733

Conference Report: Highlights from the 15th St Gallen International Breast Cancer Conference 15–18 March, 2017, Vienna: tailored treatments for patients with early breast cancer

Abstract | Full Article | PDF Published: 07 Apr 2017 / DOI: 10.3332/ecancer.2017.732

Conference Report: Highlights from the ecancer Future Horizons in Lung Cancer conference, 1–2 September 2016: Focusing on the future of treatment for NSCLC and SCLC

Abstract | Full Article | PDF Published: 23 Mar 2017 / DOI: 10.3332/ecancer.2017.729



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence